ALSO NOTED: NicOx posts positive osteoarthritis data; Genzyme snares diagnostics unit; Infinity regains program rights; and muc

> France's NicOx has posted positive data from a late-stage study of naproxcinod for osteoarthritis. Release

> Genzyme is plunking down $56 million to buy the diagnostics arm of Canada's Diagnostic Chemicals. Report

> Infinity Pharmaceuticals has regained from MedImmune all development and worldwide commercialization rights for Infinity's Hedgehog cell-signaling pathway inhibitor program, including its lead candidate IPI-926. Release

> Crucell subsidiary Berna Biotech has sold all the 2.9 million shares it owned in Switzerland's Pevion Biotech to other shareholders of Pevion. Release

> Cambria Biosciences has been awarded five grants from multiple organizations totaling $5 million. Release

> A new study may throw a big wet blanket over the market for ADHD drugs. According to the BBC, which obtained data from an unfinished, long-term study, meds aren't an effective way to treat attention deficit hyperactivity disorder. Report

> Free pens and notepads and magnets emblazoned with drug logos--what would a hospital be without them? It appears Pittsburgh is about to find out. Report

> Maybe drug-coated stents aren't so bad after all. Report

> The Vioxx saga may seem to be drawing to a close, but the chatter about it has just begun. Report

And Finally… Optimism is hard-wired into most of our brains, researchers say. One group that has proved to be an exception to the rule: Lawyers. Article

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.